CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,409,000 | -4.4% | 350,000 | -32.3% | 1.14% | +133.1% |
| Q3 2021 | $10,889,000 | -67.0% | 517,280 | -70.5% | 0.49% | -65.8% |
| Q2 2021 | $33,032,000 | -2.4% | 1,752,346 | -20.9% | 1.43% | +20.3% |
| Q1 2021 | $33,832,000 | +2.6% | 2,214,138 | -5.2% | 1.19% | -19.2% |
| Q4 2020 | $32,959,000 | -7.1% | 2,335,889 | +3.2% | 1.47% | -28.2% |
| Q3 2020 | $35,473,000 | -12.6% | 2,263,770 | -2.3% | 2.05% | -29.6% |
| Q2 2020 | $40,587,000 | -16.9% | 2,316,628 | -30.2% | 2.91% | -34.2% |
| Q1 2020 | $48,816,000 | -42.1% | 3,320,801 | -1.6% | 4.42% | -44.1% |
| Q2 2019 | $84,379,000 | +9.8% | 3,375,169 | 0.0% | 7.91% | +3.2% |
| Q1 2019 | $76,819,000 | -32.5% | 3,375,169 | -11.0% | 7.66% | -47.3% |
| Q4 2018 | $113,727,000 | +4.7% | 3,792,169 | 0.0% | 14.52% | +32.6% |
| Q3 2018 | $108,646,000 | – | 3,792,169 | – | 10.95% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |